International Research Journal of Biological Sciences _____ ISSN 2278-3202
Vol. **10(1),** 45-52, February **(2021)** *Int. Res. J. Biological Sci.*

Review Paper

Current updates on Vaccine with SARS-COV-2 – A review

Shukla Sakshi and Pandey Chitranshu
Department of Biotechnology, MRD Life Sciences Pvt. Ltd. Lucknow, India
chitranshupandeyniu@gmail.com

Available online at: www.isca.in, www.isca.me
Received 20th June 2020, revised 30th September 2020, accepted 3rd November 2020

Abstract

SARS-CoV-2 pivotal agent of coronavirus disease, initially appeared in China in late December 2019. This has since contaminated in excess of eight lakhs seventy thousands people and gave rise to in excess of forty three thousands deaths worldwide. Here, we explore SARS-CoV-2 prophylactic and therapeutic strategies with prominence on the vaccine production and their obstacles. Vaccines are quickly evolving but would possibly emerge quite late to impact a possible pandemic's first wave. Important lessons for the production of vaccines here against quickly evolving viruses, however, may be studied. Importantly, vaccines with SARS-CoV-2 would be necessary to reduce mortality and morbidity if virus is identified in the population.

Keywords: Covid-19, SARS-CoV-2, Mortality, morbidity, antibody titer, epidemic.

Introduction

Many instances of unidentified etiological pneumonia were recorded in *China's Wuhan* city on December 31, 2019. The infection began early November or December[1], the number of instances increased rapidly; China registered excess of 80,000 diseases since 15 March 2020, as well as in excess of 3,000 casualties. By the time of this analysis (7 may 2020), the outbreak, known as COVID-19 (Coronavirus infection 2019), had gotten pandemic and transmitted in excess of 203 countries and regions, together with community spread in countries namely, Germany, the USA, , Spain, Singapore, Iran, etc. Since April 1, it had been recorded over and above 870,000 instances and 43,000 casualties worldwide, including significant development in reports in several nations. The outbreak causative agent was rapidly pinpointed as group 2 coronavirus or betacoronavirus with such a genetic sequence strongly linked to the 2003 SARS (severe acute respiratory syndrome coronavirus), which named current virus as SARS-CoV-2[2]. SARS-CoV-2 originally emerged in bats which was possibly amplified in an intermittent host. Preliminary work has shown that ACE2 (angiotensin-converting enzyme 2) can be used as receptor by it from, bats, cats, swine, NHPs (non-human primates), ferrets, and humans[3]. Imparting of the disease to a lapdog in Hong Kong indicates SARS-CoV-2 can identify canine ACE2 as well. Some studies have suggested pangolines, endangered animals that are sold unlawfully in Asia or elsewhere, as a possible host for amplification[4]. Earlier China's data indicated that while many instances of Coronavirus disease present clement to moderate pathology, about twenty percent of instances are severe[5]. The case fatality risk (CFR) appears to be based on time of life, with a greater proportion of elderly people, particularly men, as well as an average interim Case Fatality Rate of about 1-3%. The many people with unnoticed, mild instances may be much greater than the reported case figure, resulting in fairly low infections fatality rate (IRF).

Coronaviruses

Sever acute respiratory syndrome coronavirus 2 belongs to family of Coronaviridae, whose individuals are identified for the crown-like presentation underneath the EM (electron microscope) caused by the glycoprotein that decorate surface of viruses. In families, 2 subfamilies are comprised: Orthocoronavirinae and Letovirinae. The genera of orthcoronavirinae are Betacoronavirus, Alphacoronavirus, Delta coronavirus and Gamma coronavirus. Beta coronaviruses and Alpha coronaviruses usually only invade mammals, while deltacoronaviruses and gamma coronaviruses generally invade avian and often mammalian species[6]. Coronaviruses are widespread human viruses; 2 kinds of alphacoronaviruses (NL63 and 229E) and 2 varieties of betacoronavirus (HKU1 and OC43) spread in humans, leading general colds. Many infective human coronaviruses comprise MERS-CoV, SARS-CoV-1, and SARS-CoV-2, both of that belong to betacoronaviruses (group 2). Coronaviruses contain wide (30 + kb) (+) ssRNA genome coding for multiple ORFs (open reading frames) 1 frame codes spike protein (S protein), a fusion protein which belongs to class first, that arbitrate the virus' attachment to surface receptors of host cells accompanied by endosomal absorption (for certain coronaviruses). Proteolytic S-protein cleavage and viral and endosomal membrane fusion cause the viral RNA discharge into the cytosol of cell[7]. The RNA incorporate a cap structure at 5 prime and poly (A) tail at 3 prime that ads in expression of replicase, which is encrypted by about 2/3 part of genome. The remaining portion of genome encodes for the accessories

proteins and structural proteins. The expression of replicase leads formation of 2 polyproteins: pp1ab and pp1a; close to 16 nonstructural proteins (nsps) are included[7].

Nonstructural proteins are produced by processing of pp1ab and pp1a by 2-3 viral specific protease encrypted within replicas several nonstructural proteins then organize into the replicase-transcriptase system which generates new viral genome, anti-sense genome and RNAsub genomic that works as mRNA in the host cell cytosol. Matrix (M) protein, Structural (S) proteins, and (E) envelope protein are then produced and incorporated into the vesicular tubular cluster (VTC). A less than half of coronaviruses also encrypts HE (esterase hemagglutinin). In several coronaviruses, the Structural protein (s) is frequently bisected by furin-like enzymes into 2 subunits, S2 and S1. Nucleoprotein is associated with genomic RNA after that develops into the VTC, creating particles of viruses[7]. Virions are transferred in vesicles to surface of cell after assembly, and are discarded out of cell. There are also certain helper proteins released, that tend to be essential for leading infection, but most are not operationally characterized.

Therapeutics to Sever acute respiratory syndrome coronavirus 2 infections

Pathological test with nt (neucliotude) similar remdesivir (Clinical-Trials.gov: NCT04280705, NCT04252664, NCT0425 7656, etc.) and inhibitors of protease (Clinical Trials.gov: NCT04276688, NCT04255017, etc.) and perhaps another medications are proceeding in united state and china, and test results are anticipated within one or two weeks. Remdesivir acts in animal models in opposition with coronaviruses firmly linked to Sever acute respiratory syndrome coronavirus 2as well as in opposition with the associated MERS-CoV, including in non-human primates[8]. Remdesivir has also been studied for the management of infections of human Ebolavirus (and shown to be fewer effective than most other therapies, Mulangu[9]). The mechanism of action of Remdesivir as an t (nucleotide) analog is unclear but it possibly ends the formation of RNA, contributes to mutagenesis[10]. Furthermore, a combination of ritonavir and lopinavir, the two approved HIV antagonists, is being studied in clinical studies. Lopinavir is a genuine protease inhibitor, while ritonavir has been originally engineered as a protease inhibitor but it was noticed to increase lopinavir's half-life by hindering cytochrome P450[11]. In 2003–2004 the concoction was employed compassionately as a remedy for SARS-CoV-1 and displayed certain potential[12]. The combination's efficacy was restricted in mice however significant in MERS-CoV NHP models[13]. Lopinavir's mode of action is unclear but it probably impedes one or more proteases of coronavirus. Many other medication choices with continuing or arranged clinical testing involve quantity of recombinant human angiotensin-converting enzyme 2 to nullify the virus as well as inhibit damage to the lungs (Clinical Trials.gov: NCT04287686), and utilizing umifenovir, a inhibitors of fusion[14]. A further fascinating choice is the usage of passive antibody as a therapy; pathological tests to evaluate this are underway in China (Clinical-Trials.gov: NCT04264858, placebo control, not yet recruiting), and compassionate usage of this technique has recently begun in the United State (e.g., Mount Sinai Medical Center, NY). Likewise, IgG extracted from genetically modified cows may be employed, as this approach has been effective in animal models for MERS-CoV[15]. Further in clinical trials, safety tests were performed (ClinicalTrials.gov: NCT02788188). Most of these tests would have results in months' time, and if ritonavir plus lopinavir (produced by Aluvia and AbbVie as Kaletra, respectively) and remdesivir (produced by Gilead) show efficacy, they may effectively be commonly employed within a less time. Compassionate usage of such medications for SARS-CoV-2 outbreaks has already been reported[16].

What else is still known about the Vaccine Formulation for Betacoronavirus?

During the H1N1 influenza pandemic of 2009, Vaccine manufacturers moved their development pipelines swiftly from manufacturing trivalent vaccines to monovalent vaccines for pandemic. It was essentially just a shift in strains and defined and accepted processes, set release parameters and could use existing correlates of safety[17]. However, it waited 6 months for the vaccine to be available for delivery and usage, and it arrived very late to affect the 2nd pandemic outbreak that had taken place in the United State, in late 2009. Such moment, we are experiencing a special threat as a virus which has just arose in humans, and the reaction would be more complicated as there are no current vaccines or coronavirus vaccine manufacturing processes available. Vaccine engineering has advanced greatly in the past decade, involving the production of many DNA and RNA vaccine candidates, approved recombinant vector vaccines (e.g., Ervebo), vaccine that is made up of recombinant protein (e.g., Flublok,) and vaccine which is based on cell (e.g., Flucelvax,). Sever acute respiratory syndrome coronavirus 2 was detected in fastest time and the Chinese researchers quickly made its genomic sequence widely available[3]. Moreover, we learn from research on Sever acute respiratory syndrome coronavirus 1 and the associated Middle Eastern respiratory syndrome coronavirus vaccines that the spike protein on the virus surface is an attractive goal for a vaccine.

In Sever acute respiratory syndrome coronavirus 2 and Sever acute respiratory syndrome coronavirus 1 this protein comes into contact with an ACE2 receptor, and antibodies attacking the spike may disrupt with such a binding, thus defusing the virus. The framework of the structural (S) protein of Sever acute respiratory syndrome coronavirus 2was resolved at high resolution in quick time, which adds value to our interpretation of this vaccine goal[18]. Therefore, a target specific antigen we have, that may be integrated into advanced platforms for vaccines. Several SARS-CoV-1 vaccines were designed and validated in models of animals, namely vectored vaccines, inactivated vaccines and recombinant Spike-protein vaccines[19.]

Many of these vaccines shield the animals from SARS-CoV-1 threats, though some do not stimulate immunity which prevents effective virus infection into the host. In certain instances, vaccination with the attenuated virus leads to illnesses such as eosinophil infiltration and lung damage in a mouse model[20]. In a further research, inactivated Sever acute respiratory syndrome coronavirus 1 vaccines vaccination led to disease enhancement in one Non-Human Primate whereas 3 animals were protected from problem[21]. Specific epitopes on the Structural protein were identified as protective in the same research, while immune response to others appeared to strengthening disease. Nevertheless, vaccination is correlated with better longevity, decreased virus loads and/or reduced morbidity relative to that of not vaccinated animals in almost every situation. Similar results for the MERS-CoV vaccines were recorded[22]. Furthermore, while coronavirus-related vaccines are successful in animal models, we have to assume that vaccines produced for Sever acute respiratory syndrome coronavirus 2 are safe enough. Significant reason for successful production of the coronavirus vaccine may be a reduction in the antibody responses. Human coronavirus infection does n't influence long-lived Reponses of antibody, and individual reinfection with the identical virus is probable after a prolonged duration of time (but just in a minority of individuals and culminating in mild symptomatology), as reported in human obstacle research[23]. Antibody levels in people who survived infections with Sever acute respiratory syndrome coronavirus 1or Middle Eastern Respiratory Syndrome Coronavirus often disappears after two–three years[24]. Nonetheless, in the short term re-infections are impossible. Importantly, re-infections have recently been reported after days of recovery but seem to be the effects of false negative findings[25]. They could happen, however, when humoral immunity begins to fade over the years. In a situation wherein the virus itself becomes widespread and actually causes repeated periodic outbreaks, an efficient SARS-CoV-2 vaccine would need to surmount those issues to safeguard. Infection with SARS-CoV-2 triggers the severest pathology in people over 50 years of age. The explanation for that is not explicit, however in sensitive younger people most viral illnesses have milder symptoms than in sensitive older adults. Since older people get more impacted, Development of vaccinations which safeguard this segment of society will be significant. Sadly, older people usually react less well to vaccinations due to aging of immune systems[26]. Precise treatments for this segment of society provide many adjuvant or antigen or to influenza that is troublesome for older people[27]. In elderly people, safety seems to require higher titers of neutralization against the influenza than in young people[28], and the problem for SARS-CoV-2 may require to be discussed. If vaccination is not successful in older people, they may still help implicitly when vaccination would avoid spread of the virus in young people. Just a limited range of vaccine with SARS-CoV-1 made this through non-pharmaceutical efforts to phase I clinical studies until funding was dried up due to elimination of the virus from the world population although occurrence statistics were still low. The findings of these studies, conducted with a vaccine of inactivated virus and a DNA vaccine based on spike, are promising even though the vaccinations were safe and caused antibody titers to be neutralized[29]. Few antibodies (monoclonal) which are derived mostly toward the SARS-CoV-1, such as CR3022[30] may cross-react with SARS-CoV-2 receptor binding region. Moreover, as such vaccines haven't been more advanced than stage I, these are not safe for use at present. Middle Eastern Respiratory Syndrome-Coronavirus vaccines, also attacking on S protein of the MERS-CoV, are under non-clinical and clinical research, involving vaccines centered on adapted, adenovirus vectors, Ankara vectors and DNA-related vaccines, and some of them are funded by the Coalition for Excellence in Epidemic Preparedness (CEPI)[31]. Nevertheless, due to the phylogenetic gap between the two viruses, it is doubtful that vaccine for Middle Eastern Respiratory Syndrome -Coronavirus vaccine striggers greater antibodies for cross-neutralizing to Sever acute respiratory syndrome coronavirus 2. However, we still can learn a great deal from such vaccines on how to proceed with the production of Sever acute respiratory syndrome corona virus 2 vaccines[32].



Figure-1: Platforms based targets under the trail for vaccine development[17].

Table-1: Summary of production of vaccine for Sever acute respiratory syndrome coronavirus 2[32].

Target	Based on action	Occurrence , Licensed Vaccines which use the similar framework	Benefits	Inconvenience
S protein	Vaccines based on RNA	No	There has to be no contagious virus. Managed, quick vaccinations. Immunogenic, and rapid development Possibility.	Reactogenicity health risks Was published.
S protein	DNA vaccines	No	There has to be no contagious virus Scale up, easy to handle, low Costs of output, heat high Stability, humanly screened for Sever acute respiratory syndrome coronavirus 1, Output Rapidly possible	Vaccine needs distribution Appliances to get better Immunogens.
S protein	Recombinant protein vaccine	Yes for (influenza and baculovirus)	There has to be no contagious virus Managed, adjutants can be used To increase immunogenicity.	Capacity for international development Maybe restricted. Epitope or antigen must be the Corroborated. Returns will be Extremely big.
S protein	Vaccines which is based on Viral vector	kits for VSV (Ervebo) but not for Some Vector Virus Vaccines	There needs to be no infectious virus. Handled, pre-clinical excellent And plenty of clinical evidence Viruses that are emerging include MERS-KV.	Immunity to vectors could be Impact negative on the vaccine Effectiveness (in feature of Chosen by vector).
Whole virion	Live diminished vaccines	Yes	Straight-forward approaches For a few licensed humans established facilities, vaccines Could be hired.	Production of infectious clones Vaccine to corona virus attenuated Sowing requires time due to Large size of the Genome. Security This will require thorough research.
Whole virion	Vaccines denatured	Yes	Methods simple For a few licensed humans established facilities, vaccines can be employed, was evaluated in Individuals with SARS-CoV-1,Adjutants can be hired to Growing immunogenicity.	Huge infectious virus loads need to be handled

The Scientist gathers those applicants for the vaccine who tend to become the furthest ahead. Yet preclinical research involves hundreds more, yet it is quite early.

Latest SARS-CoV-2 Vaccine Pipeline

The production of human-use vaccines may take many years, particularly when new methods are being used which did not have a comprehensive health check or extended to huge manufacturing. So far there are no vaccine on corona virus vaccines in the marketplace, and there is still no large-scale production potential for such vaccines (Table-1), many processes and technologies would need to be developed that can be exhausting and time - intensive for the first time. Coalition for Epidemic Preparedness Innovation has allocated funding to a number of highly creative participants in the area and most of them would probably succeed in finally designing a vaccine for SARS-CoV-2. Nevertheless, hardly any institutions and companies have a pipeline to incorporate a vaccine into late-phase studies which permit approval by federal authorities and therefore do not presently have the ability to generate the amount of medication required.

A vaccine based on mRNA, that expresses specified antigen in animal models in the vaccine following injection of messenger RNA articulated in the nanoparticles of lipid, co-constructed by the National Institutes of Health Vaccine Research Center, is presently very far away, and a clinical study step I has recently begun (Clinical Trials.gov: NCT04283461).

Table-2: Updated information of vaccine development[33].

Developers	Vaccine methods	Evidences	Status
US government and Moderna *US*	Nanoparticles of lipid entailing mRNAs for the Sever acute respiratory syndrome coronavirus 2 Protein S is inserted into arm.	Moderna generated vaccine for Zika and some other viruses, and distinct Industries also have RNA based vaccines in the clinical study, but no such vaccine has been licensed for use to date. Before the beginning of the current stage 1 trial, Sever acute respiratory syndrome coronavirus 2mRNA-1273 was not evaluated toward animals	Step 1 and step 2 research trials in progress in Seattle
the Academy of Military Medical Sciences and CanSino Biologics *Canada and China*	A non-replicating Ad5 vector able to carry the DNA sequence for spike protein of Sever acute respiratory syndrome coronavirus 2 is introduced in arm.	Adenoviruses are excellently-established vectors and CanSino used the same Ad5 platform to develop an Ebola vaccine (approved in China in 2017). The company says it produced "strong immune responses in animal models" with its Ad5-nCoV vaccine and has "a good safety profile."	Phase 1 and Phase 2 are clinical trials that are presently ongoing in Wuhan, Step 1 data reported in the on 22 May indicate that a small dose is "tolerable" in certain subjects and may triggers a strong immunity response. In Canada a step 1/2 trial was accepted for commencement.
AstraZeneca and Oxford University *UK*	Chimpanzee adenovirus vector (ChAdOx1), taking the DNA sequence for the spike protein Sever acute respiratory syndrome coronavirus 2 is inserted into arm.	After being exposed to SARS-CoV-2 6 macaques those had got a small dose of the vaccine, candidate remained healthy. A Phase 1 trial in Saudi Arabia that uses adenovirus vectoranalogues to target Middle Eastern Respiratory Syndrome - is underway.	A step 1/2 study is ongoing in the UK, and registration for a step 2/3 research follow-up has begun. AstraZeneca aims at delivering huge doses in the United Kingdom by September
Inovio Pharmaceuticals *US*	A particular device infused S protein encryptinggene through skin	Mouce and pig show immune response for viruses,	Step 1 trial undergoing with stretigies to develop one million doses of it.
Medicago	Molecule that similar to Sever acute respiratory syndrome coronavirus 2 are generated in a close similar of tobacco**.**	In research studies, the company received rotavirus vaccine close to virus-like particles and norovirus vaccine in preclinical studies.	Clinical trial is expected to begin in August
Vaxart	A pill has different antigens of SARS-CoV-2	After testing five distinct candidates for the vaccine in animals, the company selects its causes for an immune response	Probable to commence clinical testing.
Generex Biotechnology	Unraveled engineered viral proteins are immune system stimulation with proprietary Ii-Key	The organization performed in clinical trials with the Ii-Key application against infectious diseases.	The corporation is expected to start trials "within 90 days," it announced on 27 February
University of Pittsburgh School of Medicine	Micro needle patch injects spike protein via the skin.	Vaccinated mice generated Ab against Sever acute respiratory syndrome coronavirus 2 at rate which will neutralize the viruses, on basis of published data in *EBIOMedicine*	Probable to begin clinical testing in the next few month
ovavax *Australia*	Nanoparticles carrying Sever acute respiratory syndrome coronavirus 2S protein derived antigens (with Matrix-M adjuvant)	In 2012, the company developed SARS vaccine which served basis for SARS-CoV-2 vaccine candidate.	undergoing trial in phase in Australia

Comprehending the timelines

As already stated, no human coronavirus vaccines are currently approved additionally, several methods employed (vectors, production framework, etc.) are innovative and must be extensively evaluated for protection. The S protein was identified as target of vaccine, and candidates for the vaccine are being produced. It is typically followed by 2 significant phases which are usually necessary before a vaccine is introduced into testing clinically. Firstly, the vaccine is evaluated in suitable models of animal to see if it is concerned about the safety. However, model organisms for Sever acute respiratory syndrome coronavirus 2 may be hard to create. The virus doesn't really evolve in wild mice and has only caused minor symptoms in animal models that express human ACE2[34]. Many possible model organisms include NHPs and ferrets which are currently undergoing pathogenicity studies. In the lack of a model organisms which replicate disease in humans, the vaccine can be evaluated as serum from animals those are already vaccinated, can be examined in assay that is used to validate in vitro neutralization. In such cases, post-challenge safety information must also be obtained to determine risks, such as those seen with SARS-CoV-1 and MERS-CoV vaccines. In such cases, post-challenge safety information must also be obtained to determine risks, such as those seen with MERS-CoV and SARS-CoV-1 vaccines. Additionally, toxicity monitoring of vaccines in animals, i.e. in rabbits, is important. Viral risk is generally not part of this step, as only the safe operation of the vaccine would be measured. This study that must be carried out in a method that is consistent with Good Laboratory Practice usually takes three–six months to accomplish. Sections of the safety studies may be omitted for certain vaccine platforms if adequate data already are available for specific vaccines produced in the similar manufacturing process. Human-use vaccines are manufactured in procedures that conform to good manufacturing practice to assure that vaccines are of constant quality and safety. This needs dedicated equipment, skilled personnel, required paperwork, and cGMP quality raw material. Such processes must be planned or updated to fit in with SARS-CoV-2 vaccines. These procedures still do not exist for several vaccine candidates in the preclinical phase but have to be built by scratch. If the pre-clinical studies are adequate and preliminary Vaccine lots were created containing current Good Manufacturing Products Quality, may trigger clinical tests. Drug development is typical of starting with limited stage I trials to test the vaccines. Safety of candidate vaccines in human individuals. This is accompanied by Step II research (dosages and formulation to be initially determined Confirm feasibility) and eventually by step III research in that the effectiveness of yet vaccine safety requires to be illustrated in a bigger way Cohort. Even in such an exceptional case as the present one this framework could be streamlined and regulations speeded up pathway for approval could be built. If Effectiveness is seen, regulatory agencies may license a vaccine. Another significant aspect is the potential to manufacture, there needs to be ample quantities of the current Goods Manufacturing Products quality vaccine accessible. For vaccines that are based on current vaccine framework, for example live weakened or inactivated vaccines, it can be obtained fairly simple, as current infrastructure may be utilized to vaccines centered on emerging technologies for example, mRNA, such potential needs to de sign , and that usually takes a lot of time. Though, that would be advantageous if there were only a small dose number to support health practitioner staff and the individuals very susceptible, aim would be for the community to allow vaccines open to the global public.

Acquired immune response: A caveat for Vaccine Development in Future?

The immune response type Th1 generally portray in an acquired immunity to viral diseases.

Microenvironment of cytokine produced by APC (antigen presenting cell) determines the trajectory of T lymphocyte response. $CD4^+$ cells Coordinate total acquired response, whereas T cytotoxic are necessary to kill viral infected cells. Antibody mediated immune response particularly the development of sterilizing immunity, portrays a crucial role by at a later stage limiting infection and preventing re-infection ahead of time. In Sever acute respiratory syndrome coronavirus 2 both T and B cell epitopes for the S, N, M and E proteins were systematically[35].

Conclusion

A thorough examination of financial markets in last Weeks, and provided the anticipated economic effects of a pandemic, Financing for facilities to develop vaccines that will Permit quick react the evolving viruses seems a major expenditure. Such investment funds, nevertheless, without a disease outbreak uncommon until now, apart from H5 and The influenza viruses H7 subtype. Now will be the time to start spending in evolving-virus vaccines which can result in the loss of people's beings and a pressure on the world economy.

Vaccines for Sever acute respiratory syndrome coronavirus 2 may arrive very late to affect the initial Pandemic Explosion. They might however be effective if there are further waves in a post-pandemic situation in What Sever acute respiratory syndrome coronavirus 2 the cyclical virus remains to circulate. Furthermore, lessons learnt from this epidemic will help in the future, let us be adequately prepared. The viruses will remain Arrive on.

References

1. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... and Cheng, Z. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*, 395(10223), 497-506.

2. Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., ... and Yuan, M. L. (2020). A new coronavirus associated with human respiratory disease in China. *Nature*, 579(7798), 265-269.

3. Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., ... and Chen, H. D. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 579(7798), 270-273.

4. Boni, M. F., Lemey, P., Jiang, X., Lam, T. T. Y., Perry, B. W., Castoe, T. A., ... & Robertson, D. L. (2020). Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. *Nature Microbiology*, 5(11), 1408-1417.

5. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... and Du, B. (2020). Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*, 382(18), 1708-1720.

6. Cui, J., Li, F., and Shi, Z. L. (2019). Origin and evolution of pathogenic coronaviruses. *Nature reviews Microbiology*, *17*(3), 181-192.

7. Fehr, A. R., and Perlman, S. (2015). Coronaviruses: An overview of their replication and pathogenesis. In *Coronaviruses*, 1-23. Humana Press, New York, NY.

8. De Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., ... and Feldmann, H. (2020). Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proceedings of the National Academy of Sciences*, 117(12), 6771-6776.

9. Mulangu, S. (2019). PALM Writing Group; PALM Consortium Study Team. *A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med*, 381, 2293-2303.

10. Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., ... & Denison, M. R. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *MBio*, 9(2).

11. Hull, M. W. and Montaner, J. S. (2011). Ritonavir-boosted protease inhibitors in HIV therapy. *Annals of medicine*, 43(5), 375-388.

12. Chu, C. M., Cheng, V. C. C., Hung, I. F. N., Wong, M. M. L., Chan, K. H., Chan, K. S., ... and Peiris, J. S. M. (2004). Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax*, 59(3), 252-256.

13. Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., ... and Spahn, J. E. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nature Communications*, 11(1), 1-14.

14. Teissier, E., Zandomeneghi, G., Loquet, A., Lavillette, D., Lavergne, J. P., Montserret, R., ... and Pécheur, E. I. (2011). Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. *PloS one*, 6(1).

15. Luke, T., Wu, H., Zhao, J., Channappanavar, R., Coleman, C. M., Jiao, J. A., ... & Frieman, M. B. (2016). Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. *Science translational medicine*, 8(326), 326ra21-326ra21.

16. Lim, J., Jeon, S., Shin, H. Y., Kim, M. J., Seong, Y. M., Lee, W. J., ... and Park, S. J. (2020). Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. *Journal of Korean medical science*, 35(6).

17. Krammer, F., and Palese, P. (2015). Advances in the development of influenza virus vaccines. *Nature reviews Drug discovery*, 14(3), 167-182.

18. Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., ... and Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, 1-6.

19. Roper, R. L., & Rehm, K. E. (2009). SARS vaccines: where are we?. *Expert review of vaccines*, 8(7), 887-898.

20. Tseng, C. T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., ... & Couch, R. B. (2012). Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. *PloS one*, 7(4), e35421.

21. Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., ... and Morioka, H. (2016). Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. *ACS Infectious Diseases*, 2(5), 361-376.

22. Houser, K. V., Broadbent, A. J., Gretebeck, L., Vogel, L., Lamirande, E. W., Sutton, T., ... and Subbarao, K. (2017). Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. *PLoS pathogens*, 13(8), e1006565.

23. Callow, K. A., Parry, H. F., Sergeant, M., and Tyrrell, D. A. J. (1990). The time course of the immune response to experimental coronavirus infection of man. *Epidemiology and Infection*, 105(2), 435-446.

24. Wu, L. P., Wang, N. C., Chang, Y. H., Tian, X. Y., Na, D. Y., Zhang, L. Y., ... and Liang, G. D. (2007). Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases*, 13(10), 1562.

25. Kim, D. D., & Goel, A. (2020). Estimating case fatality rates of COVID-19. *The Lancet infectious diseases*, 20(7), 773-774.

26. Sambhara, S., & McElhaney, J. E. (2009). Immunosenescence and influenza vaccine efficacy. *Vaccines for Pandemic Influenza*, 413-429.

27. Tsai, T. F. (2013). Fluad®-MF59®-adjuvanted influenza vaccine in older adults. *Infection and chemotherapy*, 45(2), 159-174.

28. Benoit, A., Beran, J., Devaster, J. M., Esen, M., Launay, O., Leroux-Roels, G., ... and Jackson, L. A. (2015). Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. *In Open forum infectious diseases*, 2(2). Oxford University Press.

29. Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., ... and Bailer, R. T. (2008). A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. *Vaccine*, 26(50), 6338-6343.

30. Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., ... and Ying, T. (2020). Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerging microbes and infections*, 9(1), 382-385.

31. Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019). Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. *Frontiers in Microbiology*, 10, 1781.

32. Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., ... and Kong, W. P. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proceedings of the National Academy of Sciences*, 114(35), E7348-E7357.

33. Akst, J. (2020). COVID-19 vaccine frontrunners. *The Scientist*. 7.

34. Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., ... & Qin, C. (2020). The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature*, 583(7818), 830-833.

35. Kaslow, D. C. (2020). Certainty of success: three critical parameters in coronavirus vaccine development. *NJP Vaccines*, 5(1), 1-7.